Company intelligence / Profile preview

Joras Oncology

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Joras Oncology is a pre-clinical stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of cancer. The company's primary focus is on targeting the eukaryotic translation initiation factor 4E (eIF4E), a key regulator of protein synthesis that is frequently overexpressed in various malignancies. By inhibiting eIF4E, Joras Oncology aims to selectively disrupt the production of oncogenic proteins that drive tumor growth, survival, and metastasis. Their lead research efforts are directed toward creating potent and selective therapies for both solid tumors and hematologic cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Joras Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Joras Oncology.

Explore the full profile